Cargando…

Direct-Acting Antivirals for HCV Treatment in Decompensated Liver Cirrhosis Patients: A Systematic Review and Meta-Analysis

DAA therapy is known to clear hepatitis C virus infection in patients with decompensated cirrhosis (DC). However, the safety and benefits of DAA in DC remain unclear, especially with the use of protease inhibitors (PI). Therefore, we evaluated the efficacy and clinical safety of DAA in DC patients a...

Descripción completa

Detalles Bibliográficos
Autores principales:	An, JiHyun, Park, Dong Ah, Ko, Min Jung, Ahn, Sang Bong, Yoo, Jeong-Ju, Jun, Dae Won, Yim, Sun Young
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9506163/ https://www.ncbi.nlm.nih.gov/pubmed/36143302 http://dx.doi.org/10.3390/jpm12091517

Ejemplares similares

Direct-Acting Antivirals and the Risk of Hepatitis B Reactivation in Hepatitis B and C Co-Infected Patients: A Systematic Review and Meta-Analysis
por: Oh, Joo Hyun, et al.
Publicado: (2022)

Long-term survival and clinical outcomes following direct-acting antiviral (DAA) treatment in HCV decompensated cirrhosis in Brazil: a real-world study
por: Pereira, Gustavo H., et al.
Publicado: (2022)

Telomere Length Increase in HIV/HCV-Coinfected Patients with Cirrhosis after HCV Eradication with Direct-Acting Antivirals (†)
por: Molina-Carrión, Silvia, et al.
Publicado: (2020)

Immunological Predictors of Nonresponse to Directly Acting Antiviral Therapy in Patients With Chronic Hepatitis C and Decompensated Cirrhosis
por: Childs, Kate, et al.
Publicado: (2017)

Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis
por: Pageaux, Georges-Philippe, et al.
Publicado: (2022)

Antiviral Therapy in HCV-infected Decompensated Cirrhotics
por: Danish, Fazal A., et al.
Publicado: (2010)

Long term outcome of antiviral therapy in patients with hepatitis B associated decompensated cirrhosis
por: Ju, Young-Cheol, et al.
Publicado: (2018)

HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals
por: Rice, Donald P., et al.
Publicado: (2016)

Risk of adverse outcomes following treatment with direct acting antiviral drugs in HCV infected patients with liver cirrhosis
por: Riaz, Hafiza Arooba, et al.
Publicado: (2023)

Screening and surveillance of oesophageal varices in patients with HCV‐positive liver cirrhosis successfully treated by direct‐acting antiviral agents
por: Ciancio, Alessia, et al.
Publicado: (2022)

Fecal Microbiota Transplantation in Decompensated Cirrhosis: A Systematic Review on Safety and Efficacy
por: Hong, Annie S., et al.
Publicado: (2022)

A Case of Hepatitis C-Related Decompensated Cirrhosis Observed by MRI Imaging Data During Treatment With Direct-Acting Antiviral Agents
por: Nakamura, Atsushi, et al.
Publicado: (2021)

HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents
por: Angeletti, Andrea, et al.
Publicado: (2019)

The ‘Viennese epidemic’ of acute HCV in the era of direct‐acting antivirals
por: Chromy, David, et al.
Publicado: (2022)

Prognostic value of liver stiffness in HIV/HCV-Coinfected patients with decompensated cirrhosis
por: Pérez-Latorre, Leire, et al.
Publicado: (2018)

Transplantation of HCV Viremic Livers into HCV Viremic Recipients Followed by Direct-acting Antiviral Therapy
por: Kapila, Nikhil, et al.
Publicado: (2019)

Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era
por: Stevenson, Heather L., et al.
Publicado: (2016)

Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation
por: Martin, Natasha K., et al.
Publicado: (2016)

Role of biomarkers as predictors of acute kidney injury and mortality in decompensated cirrhosis
por: Jo, Sang Kyung, et al.
Publicado: (2019)

Posttreatment liver function, but not baseline liver function stratifies patient survival after direct-acting antiviral treatment in decompensated cirrhosis with hepatitis C virus
por: Tahata, Yuki, et al.
Publicado: (2023)

Survival of HIV/HCV co-infected patients before introduction of HCV direct acting antivirals (DAA)
por: Dold, L., et al.
Publicado: (2019)

HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients
por: Brochado-Kith, Óscar, et al.
Publicado: (2021)

Decrease of Alpha-fetoprotein in Patients with Cirrhosis Treated with Direct-acting Antivirals
por: Nguyen, Kelvin, et al.
Publicado: (2017)

Genetic Barrier to Direct Acting Antivirals in HCV Sequences Deposited in the European Databank
por: Kliemann, Dimas Alexandre, et al.
Publicado: (2016)

HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)
por: La Manna, Gaetano
Publicado: (2018)

Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients
por: Armando, Calogero, et al.
Publicado: (2019)

Direct-Acting Antiviral Agents for HCV-Associated Glomerular Disease and the Current Evidence
por: Fabrizi, Fabrizio, et al.
Publicado: (2019)

Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV
por: Patel, Sonia Vibhakar, et al.
Publicado: (2020)

In HCV-related liver cirrhosis, local pulse wave velocity increases and in decompensated patients correlates with poorer survival
por: Huang, Chien-Hao, et al.
Publicado: (2019)

Liver Remodeling on CT Examination in Patients with HCV Compensated Cirrhosis Who Achieved Sustained Virological Response after Direct-Acting Antivirals Treatment
por: Mihai, Florin, et al.
Publicado: (2020)

Baseline Plasma Metabotype Correlates With Direct-Acting Antiviral Therapy Nonresponse for HCV in HIV–HCV Coinfected Patients
por: Tripathi, Gaurav, et al.
Publicado: (2022)

Combination with portosystemic shunt occlusion and antiviral therapy improves prognosis of decompensated cirrhosis
por: Tamai, Hideyuki, et al.
Publicado: (2020)

Need to Face Liver Cirrhosis after HCV Cure with Antivirals
por: Soriano, Vicente, et al.
Publicado: (2017)

Can We Trust Safety of Tenofovir Disoproxil in Patients with Decompensated Cirrhosis?
por: Oh, Hyunwoo, et al.
Publicado: (2017)

354. Efficacy of Second-Generation Direct Acting Antivirals in the Setting of HCV/HIV Co-infection and Cirrhosis: A Review of Real-World Treatment Experiences
por: Saba, Nicholas, et al.
Publicado: (2019)

Long-Term Hepatocellular Carcinoma Development and Predictive Ability of Non-Invasive Scoring Systems in Patients with HCV-Related Cirrhosis Treated with Direct-Acting Antivirals
por: Caviglia, Gian Paolo, et al.
Publicado: (2022)

Augmenting central arterial stiffness following eradication of HCV by direct acting antivirals in advanced fibrosis patients
por: Cheng, Pin-Nan, et al.
Publicado: (2019)

Liver decompensation predicts ribavirin overexposure in hepatitis C virus patients treated with direct-acting antivirals
por: Guardigni, Viola, et al.
Publicado: (2017)

Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis
por: Toshikuni, Nobuyuki
Publicado: (2017)

Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination
por: Virlogeux, Victor, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_75r1br1ohkvngt937k9k9lkujm